Management to Hold Conference Call at 8:30 a.m. EDT TEL AVIV, Israel , Aug.
8, 2024 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX ) (TASE: BLRX), a commercial stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today announced that it will release its unaudited financial results for the second quarter ended June 30, 2024 on Thursday, August 15, 2024 , before the U.S.
markets open. The Company will host a conference call at 8:30 a.m.
EDT featuring remarks by Philip Serlin , Chief Executive Officer. To access the conference call, please dial +1-888-281-1167 from the U.S.
or +972-3-918-0685 internationally. A live webcast and a replay of the call can be accessed through the event page on the Company's website. Please allow extra time prior to the call to visit the site and download any necessary software to listen to the live broadcast.
The call replay will be available approximately two hours after completion of the live conference call. A dial-in replay of the call will be available until August 19, 2024 ; please dial +1-888-295-2634 from the US or +972-3-925-5904 internationally. About BioLineRx BioLineRx Ltd.
(NASDAQ/TASE: BLRX) is a commercial stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases. The company's first approved product is APHEXDA® (motixafortide) with an indication in the U.S.
for stem cell mobilization for autologous transplantation in multiple myeloma. BioLineRx is advancin.